Lantheus stock is trading -39.01% below its average target price of $119.63 after marking a 7.8% during today's afternoon session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $110.0 to $130.0 per share.
Lantheus has an average level of shares sold short, at 9.6% of its total share float. The stock's short ratio (also called days to cover) is 5.77. Since 2.8% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Institutional investors own 100.9% of Lantheus's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Lantheus
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Blackrock Inc. | 12% | 8,066,562 | $588,536,356 |
| 2023-06-30 | Vanguard Group Inc | 10% | 7,182,982 | $524,070,360 |
| 2023-06-30 | Alliancebernstein L.P. | 4% | 2,655,559 | $193,749,582 |
| 2023-06-30 | State Street Corporation | 3% | 2,335,904 | $170,427,553 |
| 2023-06-30 | Price (T.Rowe) Associates Inc | 2% | 1,526,786 | $111,394,305 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 1,399,876 | $102,134,951 |
| 2023-06-30 | Dimensional Fund Advisors LP | 2% | 1,362,204 | $99,386,402 |
| 2023-06-30 | Farallon Capital Management Llc | 2% | 1,360,500 | $99,262,078 |
| 2023-06-30 | Invesco Ltd. | 2% | 1,311,854 | $95,712,866 |
| 2023-06-30 | Hood River Capital Management LLC | 2% | 1,174,616 | $85,699,982 |
